0
Axovant Gene Therapies Ltd. Banner Image

Axovant Gene Therapies Ltd. has reached its limit for free report views

Work for Axovant Gene Therapies Ltd.? Upgrade Your Profile and unlock all your annual reports.

Axovant Gene Therapies Ltd.

  • Ticker AXGT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Axovant Gene Therapies Ltd. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Their current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating productMore candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations.
Axovant Gene Therapies Ltd.

Most Recent Annual Report

Axovant Gene Therapies Ltd. MOST RECENT 2020 Form 10K

Report Locked. Axovant Gene Therapies Ltd. has reached its limit for free report views.